Back

Relative and absolute benefit of dapagliflozin using different eGFR estimates: insights from DAPA-HF trial

19 May 2025 (15:00 - 15:45)
Organised by: Logo
Congress Presentation Part of: Advances in heart failure therapeutics Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Paolo Tolomeo

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Refining definitions of severe and advanced heart failure: insight from the swedish heart failure registry to optimize trial design and improve referral to advanced therapies
Doctor F. Guidetti (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Association between neutrophil-to-lymphocyte ratio, exercise capacity and outcomes in patients with heart failure and reduced ejection fraction
Doctor E. Rodenas Alesina (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Sodium zirconium cyclosilicate for the management of hyperkalaemia in patients with heart failure with reduced ejection fraction - the REALIZE-K open-label run-in phase
Professor M. Petrie (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Cardiac rhythm management devices in patients with heart failure - preliminary results of the DIRECT HF international survey on patients' needs and perceptions
Ms R. Monroe (Charlotte, US)
Abstract Slides Video

Access the full session

Session thumbnail
Advances in heart failure therapeutics

The Event

Event poster

Heart Failure 2025

19 May 2025 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Effects of Dapagliflozin in Patients with Heart Failure and Deterioration of Kidney Function Below eGFR 25ml/min/1.73m^2
thumbnail
Congress Presentation
The role of cystatin c-creatinine eGFR difference in assessing renal function and its correlation with frailty in patients with worsening heart failure: a real-world study
thumbnail
Congress Presentation
Revealing the prognostic accuracy of different gLomerular filtration rate estimation formulas in heart failure patients with reduced ejection fraction and various degrees of kidney failure: the RENAL-

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources